amikacin for treatment of patients with bronchiectasis and chronic obstructive pulmonary disease(COPD).MethodsPatients with bronchiectasis and COPD in a hospital from January 1, 2016 to December 31, 2016 were selected. They were randomly divided into trial group and control group. Two groups both received conventional treatment, control group was treated with 0.9% sodium chloride for bronchoalveolar lavage; trial group were given topical use of amikacin solution on the basis of conventional treatment. Efficacy of treatment, laboratory test results, and incidences of adverse reactions were compared between two groups of patients.ResultsA total of 47 patients were included in the study, 24 were in trial group and 23 in control group. After treatment, the total efficacy rate of trial group was significantly higher than that of control group (95.83% vs 69.57%, P<0.05). Pulmonary function (VC, FEV1, FEV1/FVC), peripheral white blood cell count (WBC), neutrophil percentage (N%), highsensitivity Creactive protein (hsCRP), and procalcitonin (PCT) levels in two groups of patients significantly improved after treatment compared with those before treatment, differences were all statistically significant (P<0.05). After treatment, improvement of pulmonary function in trial group was better than that of control group, WBC count, N%, hsCRP, and PCT were lower than control group, differences were all statistically significant (P<0.05); there was no significant difference in the incidence of adverse reactions between two groups（χ2=0.090，P=0.956）.ConclusionTherapeutic efficacy of BAL and topical amikacin in the treatment of patients with bronchiectasis and COPD is superior to 0.9% sodium chloride lavage, it does not increase the incidence of adverse reaction, can shorten length of hospital stay, and is worthy of clinical application.